Heng Zhou
Merck & Co., Inc., Rahway, NJ, USA (United States) · 48 works · 609 citations · h-index 10
Top works
- Accuracy, Safety, and Reliability of Novel Phase I Trial Designs
- BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints
- Comparative review of novel model‐assisted designs for phase I clinical trials
- Bayesian optimal phase II clinical trial design with time‐to‐event endpoint
- A hybrid design for dose‐finding oncology clinical trials
- Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials
- Accuracy, Safety, and Reliability of Novel Phase I Designs—Response
- Optimal two-stage designs for exploratory basket trials
- Statistical and practical considerations in planning and conduct of dose-optimization trials
- Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies
- BOP2-TE: Bayesian optimal phase 2 design for jointly monitoring efficacy and toxicity with application to dose optimization
- A Generalized Framework of Optimal Two-Stage Designs for Exploratory Basket Trials
- Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials
- Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials
- Phase I Cancer Clinical Trial Design: Single and Combination Agents
- Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.
- An optimal two-stage exploratory basket trial design with aggregated futility analysis
- A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
- A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities
- Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective